Onderzoekers presenteren bevindingen op EASL International Liver Congress™ 2021, 23-26 juni 2021
PARIJS & WALTHAM, Mass. -(BUSINESS WIRE)- Echosens, een hoogtechnologisch bedrijf dat de FibroScan®-familie van producten aanbiedt, kondigt vandaag de wereldwijde lancering aan van FibroScan-gebaseerde Agile-scores om gemakkelijk gevorderde fibrose en cirrose op te sporen bij patiënten met non-alcoholic fatty liver disease (NAFLD), het aantal vals-positieve gevallen te verminderen in vergelijking met leverstijfheidsmeting door middel van vibration controlled transient elastography (LSM door VCTE™) alleen, levercomplicaties nauwkeurig te voorspellen en, in de komende jaren, patiënten te identificeren die in aanmerking komen voor farmaceutische behandelingen.
Echosens Launches New FibroScan-Based Scores Agile 3+ & Agile 4: Identifies Advanced Fibrosis and Cirrhosis, Predicts Clinical Outcomes, Improves Patient Management
Researchers present findings at EASL International Liver Congress™ 2021, June 23-26, 2021
PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, a high-technology company offering the FibroScan® family of products, today announces the global launch of FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients, reduce the number of false positive cases compared to liver stiffness measurement by vibration controlled transient elastography (LSM by VCTE™) alone, accurately predict liver complications and, in coming years, identify patients eligible for pharmaceutical treatments.
Learn more about myFibroScan here.
“Agile scores deliver a new level of value to the FibroScan solution by enhancing capabilities in the management of non-alcoholic fatty liver patients, improving early identification of those who are at risk and helping providers initiate the right intervention,” says Dominique Legros, Group CEO, Echosens. “Agile scores also make it possible to more accurately predict liver complications and identify patients sooner for hepatocellular carcinoma and portal hypertension screening.”
Currently available noninvasive tests, including FIB-4 and LSM by VCTE, are highly effective in excluding cirrhosis and advanced fibrosis, but their ability to rule them in is moderate. Agile 3+ can improve the identification of advanced fibrosis among patients with NAFLD and may reduce the necessity of liver biopsy in this patient population. Agile 4 improves the identification of cirrhotic patients and may reduce the need for liver biopsy for this diagnostic target, as well as identify patients for hepatocellular carcinoma and esophageal varices screening.
The worldwide prevalence of NAFLD is about 25%, with a close association with Type 2 diabetes, obesity and metabolic syndrome. The burden of this disease has increased 10% since 2005 in parallel to rising rates of obesity.
Jon Gingrich, CEO, Echosens North America: “Research demonstrates that broad deployment of VCTE devices, like FibroScan, is a financially advantageous solution to address the fatty liver disease (FLD) epidemic.”
To learn more visit here.
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
201.641.1911 x 14